Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting.

Matias A Avila, Jean-François Dufour, Alexander L Gerbes, Fabien Zoulim, Ramon Bataller, Patrizia Burra, Helena Cortez-Pinto, Bin Gao, Ian Gilmore, Philippe Mathurin, Christophe Moreno, Vladimir Poznyak, Bernd Schnabl, Gyongyi Szabo, Maja Thiele, Mark R Thursz

Journal: Gut 2020;69(4):764-780

PMID: 31879281

Free Full Text on PubMed Central View on PubMed

Abstract

Alcohol-related liver disease (ALD), which includes a range of disorders of different severity and is one of the most prevalent types of liver disease worldwide, has recently regained increased attention. Among other reasons, the realisation that any alcohol intake, regardless of type of beverage represents a health risk, and the new therapeutic strategies tested in recently published or undergoing clinical trials spur scientific interest in this area.In April 2019, Gut convened a round table panel of experts during the European Association for the Study of the Liver International Liver Congress in Vienna to discuss critical and up-to-date issues and clinical trial data regarding ALD, its epidemiology, diagnosis, management, pathomechanisms, possible future treatments and prevention. This paper summarises the discussion and its conclusions.

Address: Hepatology, CIBERehd, IdiSNA, CIMA, University of Navarra, Pamplona, Spain [email protected].; Hepatology, Department of Clinical Research and University Clinic for Visceral Surgery and Medicine, Inselspital, University of Bern, Bern, Switzerland.; Liver Centre Munich, Department of Medicine II, University Hospital, LMU Munich, Munich, Germany.; Hepatology Department, INSERM U1052, Hospices Civils de Lyon, Cancer Research Centerl of Lyon, University of Lyon, Lyon, France.; Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, Pittsburgh Liver Research Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.; Multivisceral Transplant Unit, Gastroenterology, Department of Surgery, Oncology and Gastroenterology, Padua University Hospital, Padua, Italy.; Departamento de Gastroenterologia, CHLN, Laboratorio de Nutriçao, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.; Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, USA.; Liverpool Centre for Alcohol Research, University of Liverpool, Liverpool, UK.; Service des Maladies de l'Appareil Digestif, INSERM U795, Hôpital Huriez, Lille, France.; Service de Gastroentérologie, Hépatopancréatologie et Oncologie Digestive, CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.; Department of Mental Health and Substance Abuse, World Health Organization, Geneve, Switzerland.; Department of Medicine, University of California San Diego, La Jolla, California, USA.; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.; Department of Gastroenterology and Hepatology, and Department of Clinical Research, Odense University Hospital and University of Southern Denmark, Odense, Denmark.; Department of Metabolism, Faculty of Medicine, Imperial College, London, UK.

DOI: 10.1136/gutjnl-2019-319720